Compendium of Cancer Genome Aberrations

HAEM5:Classic Hodgkin lymphoma: Difference between revisions

(View all pending changes)
[checked revision][pending revision]
← Older editNewer edit →
VisualWikitext
No edit summary
Lynn.Hu (talk | contribs)
113 edits
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{DISPLAYTITLE:Classic Hodgkin lymphoma}}
{{DISPLAYTITLE:Classic Hodgkin lymphoma}}
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]


Line 14: Line 15:
==Primary Author(s)*==
==Primary Author(s)*==


Patricia V. Hernandez, M.D., Washington University School of Medicine
Xiaolin Hu, Ph.D., GeneDx
==WHO Classification of Disease==
==WHO Classification of Disease==


Line 79: Line 80:
!Clinical Relevance Details/Other Notes
!Clinical Relevance Details/Other Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|2p
7
|gain
|<span class="blue-text">EXAMPLE:</span> Loss
|2p13
|<span class="blue-text">EXAMPLE:</span>
|REL
chr7
|P
|<span class="blue-text">EXAMPLE:</span>
|No
Unknown
|REL amplification promotes NF-κB signaling activation (PMID: 19380639)
|<span class="blue-text">EXAMPLE:</span> D, P
|<span class="blue-text">EXAMPLE:</span> No
|<span class="blue-text">EXAMPLE:</span>
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references).
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|9p
8
|Gain
|<span class="blue-text">EXAMPLE:</span> Gain
|9p24.1
|<span class="blue-text">EXAMPLE:</span>
|CD274 (PD-L1), PDCD1LG2 (PD-L2), JAK2
chr8
|T, P
|<span class="blue-text">EXAMPLE:</span>
|Yes (PMID:20628145)
Unknown
|9p24.1 amplification drives PD-L1/PD-L2 overexpression, relevant for immune checkpoint inhibitor therapy (PMID: 20628145, 27069084)
|<span class="blue-text">EXAMPLE:</span> D, P
|
|<span class="blue-text">EXAMPLE:</span>
Common recurrent secondary finding for t(8;21) (add references).
|-
|-
|<span class="blue-text">EXAMPLE:</span>
|17p
17
|Gain
|<span class="blue-text">EXAMPLE:</span> Amp
|17q21
|<span class="blue-text">EXAMPLE:</span>
|MAP3K14
17q12; chr17:39,700,064-39,728,658 [hg38; 28.6 kb]
|P
|<span class="blue-text">EXAMPLE:</span>
|No
''ERBB2''
|MAP3K14 (NIK) gain activates alternative NF-κB signaling (PMID: 19380639)
|<span class="blue-text">EXAMPLE:</span> D, P, T
|
|<span class="blue-text">EXAMPLE:</span>
Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined.
|-
|-
|
|6q
|
|Loss
|
|6q23-24
|
|TNFAIP3
|
|P
|
|No
|
|Loss of TNFAIP3 (A20) disrupts NF-κB regulation (PMID: 19380639)
|}
|}


Retrieved from "https://test.ccga.io/index.php/HAEM5:Classic_Hodgkin_lymphoma"